Add-on Acquisition • Medical Products

Integra LifeSciences Acquires Derma Sciences

On January 10, 2017, Integra LifeSciences acquired medical products company Derma Sciences

Acquisition Context
  • This is Integra LifeSciences’ 34th transaction in the Medical Products sector.
  • This is Integra LifeSciences’ 34th transaction in the United States.
  • This is Integra LifeSciences’ 2nd transaction in New Jersey.

Explore All 2731 Add-on Acquisition Medical Products Deals - Search the Database Free


M&A Deal Summary

Date January 10, 2017
Target Derma Sciences
Sector Medical Products
Buyer(s) Integra LifeSciences
Deal Type Add-on Acquisition

Target Company

Derma Sciences

Princeton, New Jersey, United States
Derma Sciences, Inc. is an integrated manufacturer, marketer and supplier of dermatological related product lines, including: wound care, wound closure and specialty securement devices, and skin care.
Explore More Deals

Browse All 215,130 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Buyer Overview 1

Buyer

Integra LifeSciences

Princeton, New Jersey, United States

Category Company
Founded 1989
Sector Medical Products
Employees4,396
Revenue 1.6B USD (2024)
DESCRIPTION

Integra LifeSciences is a major medical technology dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedic extremity surgery, neurosurgery, and reconstructive and general surgery. Integra LifeSciences was founded in 1989 and is based in Princeton, New Jersey.


Deal Context for Buyer #
Overall 41 of 45
Sector: Medical Products 34 of 38
Type: Add-on Acquisition 31 of 33
State: New Jersey 2 of 2
Country: United States 34 of 38
Year: 2017 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-07-20 TEI Biosciences

Waltham, Massachusetts, United States

TEI Biosciences, Inc. is a biomedical company that applies its expertise in regenerative medicine to develop and commercialize novel biologic devices, including SurgiMend®, for a broad spectrum of soft tissue repair and regeneration applications – from dura and hernia repair to plastic and reconstructive surgery.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-02-15 Johnson & Johnson - Codman Neurosurgery Business

Raynham, Massachusetts, United States

Johnson & Johnson - Codman Neurosurgery Business is a global neurosurgery and neurovascular company that offers a broad portfolio of devices for hydrocephalus management, neuro intensive care and cranial surgery, as well as aneurysm coils, vascular reconstruction devices and other technologies used in the endovascular treatment of cerebral aneurysms and stroke.

Buy $1.0B